NAVINFLUOR Q2 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹758 Cr
verified against source
Revenue YoY
46%
reported change
EBITDA
₹246 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Navin Fluorine delivered a standout Q2 FY26 with ₹758 crore revenue (+46% YoY) and ₹246 crore EBITDA (+129% YoY), driving EBITDA margins to 32.5% from 20.7%—a 1,180bps expansion driven by volume growth (~90% of margin benefit), pricing gains, and operating leverage across all three verticals. HPP crossed ₹400 crore (+38%), Specialty reached ₹220 crore (+39%) with the Dec'24 plant now at optimum utilization, and CDMO surged 98% YoY to ₹134 crore ahead of Jan'26 CGMP4 supplies. Two strategic capexes totaling ₹311.5 crore were approved: 15,000MT R32 capacity (₹236.5 crore, peak revenue ₹600-825 crore, commissioning Q3 FY27) and MPP debottlenecking (₹75 crore, peak revenue ₹140-160 crore). FY26 EBITDA guidance was raised to 28-30% from the original 25%. AHF commissioning remains on track for Q3 FY26, with full HF utilization expected by 2029-30. Key risks: forex headwinds could compress margins if INR appreciates, HPP pricing remains tied to global commodity cycles, and the lumpy nature of CDMO orders creates revenue uncertainty. The company targets ₹100 million CDMO revenue and full specialty plant utilization by FY27.
Colored figures show movement against the previous available record.
Guidance to track
- Company raised full-year EBITDA margin guidance from original 25% to 28-30% based on H1 performance of 30.5%. Original guidance had more upside than downside, and H1 results validate the upward revision.
- Full-year capex expected within ₹600-700 crore range including ongoing projects and newly announced capexes (R32 expansion and MPP debottlenecking). Multi-year frame of ~₹1,000 crore over next two years.
- AHF project continues with mechanical trials underway and commissioning expected in Q3 FY26. Electronic grade HF development is also progressing.
- The 15,000MT R32 capacity (₹236.5 crore capex) is expected to generate peak annual revenue of ₹600-825 crore upon commissioning in Q3 FY27. Project based on ₹4.5-6.5/kg pricing assumption.
- Company reiterated ₹100 million aspirational CDMO revenue target with strong visibility. European MSA partner accounts for 35-40% of this target with more upside potential. Full utilization expected by FY27.
Risks flagged
- Management acknowledged forex tailwinds contributed to margin expansion in H1 but noted these have been largely absorbed by sub-sourcing costs. Future INR appreciation could pressure margins if not offset by volume growth.
- AHF plant will have significant unutilized capacity for multiple years. Full utilization expected only by 2029-30. Management frames this as 'strategic investment' but creates near-term operational inefficiency.
- Analyst repeatedly asked about contractual vs spot ratio and pricing for R32 expansion. Management deflected citing 'commercial sensitivity,' making it difficult to assess margin quality and earnings sustainability of the new capex.
- CDMO growth is heavily dependent on European MSA partner (35-40% of $100M target). Any delay or cancellation in the anchor molecule (validation ongoing, supplies starting Jan'26) could significantly impact CDMO trajectory.
Key quotes
- The growth that we are demonstrating in this quarter is coming across the verticals—it's coming from volume expansion, it's coming from pricing, it's coming from product mix, it's coming from efficiencies, it's coming from a lot of drivers around it.
- We had originally given a guidance of 25% EBITDA but we'd always said there was more upside to it than downside. Where we stand now in the first half, given the performance, I think we're well on track to be between 28 to 30% for the year.
- We are taking a very measured manner ensuring that as the capacities come up there is a market that we are servicing... these commitments are meant for the midterm. They're not short-term relationships.
- About 80-90% of our underlying growth in the margins and that effectively translates down to PAT is coming largely from volume growth. You also have some pricing tailwinds and forex tailwinds which are offset through your sourcing costs.
Research modules